Day: June 11, 2024

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

Written by Customer Service on June 11, 2024. Posted in Public Companies.

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows:Presentation Title: Empowering Peptide Self Administration with Needle-Free Smart CapsulesTrack: Pioneering Devices to Increase the Reach of Peptide APIsDate & Time: Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern timePresenting Author: Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc.Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations...

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Written by Customer Service on June 11, 2024. Posted in Public Companies.

Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the publication of Phase 2 clinical data of its DNA damage repair inhibitor drug candidate, TRC102, in patients with glioblastoma...

Apica Delivers Unmatched Data Management Capabilities with Additions to Ascent Platform

Written by Customer Service on June 11, 2024. Posted in Mergers And Acquisitions.

Apica Ascent platform 2.0 helps customers tame velocity, volume, variety, and sprawl for observability, machine, and operational data STOCKHOLM and EL SEGUNDO, Calif. , June 11, 2024 (GLOBE NEWSWIRE) — Apica, the leader in data management and active observability, today announced new capabilities for its Apica Ascent Platform. Following the company’s acquisitions of data fabric innovator LOGIQ.AI and telemetry data management pioneer Circonus, Apica has integrated capabilities from both organizations into its platform to provide deeper insights into data management. This makes it easier for customers to gather the needed data and seamlessly apply it to their systems and platforms. In addition to making two acquisitions over the last 10 months, Apica announced $16M in new capital. With this funding, it expanded its Office of the...

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

Written by Customer Service on June 11, 2024. Posted in Public Companies.

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. FDA orphan drug designation is granted for therapeutic candidates that may prevent or treat a rare disease or condition, such as acute babesiosis.WASHINGTON, June 11, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharmaceuticals”), a pharmaceutical company focused on developing new medicines for infectious...

Fairfax Announces Termination of Total Return Swaps of Ensign Energy Services Inc. and Acquisition of Common Shares

Written by Customer Service on June 11, 2024. Posted in Public Companies.

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that on June 10, 2024, it terminated total return swaps over 7,787,600 common shares (“Common Shares”) of Ensign Energy Services Inc. (“Ensign”), which had an average reference price of C$1.3182. Upon the termination of the total return swaps, Fairfax agreed with the counterparty to purchase 7,787,600 Common Shares at a price of C$2.34 per Common Share, representing 4.24% of the outstanding Common Shares. Prior to the acquisition of the Common Shares, Fairfax beneficially owned and controlled 21,800,886 of the issued and outstanding Common Shares, representing approximately 11.86% of all issued and outstanding Common Shares. Following the acquisition of the Common Shares, Fairfax beneficially owns and controls...

Treasure Global Announces 113.5% Growth in Transactions for TAZTE, its Innovative Digital F&B Management System

Written by Customer Service on June 11, 2024. Posted in Public Companies.

Projected Market for Mobile POS Payments in Malaysia to Reach US$10.04 Billion by 2028* NEW YORK and KUALA LUMPUR, Malaysia, June 11, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, is pleased to announce that TAZTE Smart F&B system (“TAZTE”), its innovative digital food and beverage (“F&B”) management system, continues to make significant strides in its development and market penetration. Transaction Growth and User EngagementTAZTE has shown impressive year-over-year growth in both transactions and user engagement. Without any additional marketing funds, the total number of transactions reached 7,540, marking a 113.5% increase. Additionally, the number of monthly transacted users rose by 55%, now totalling 3,752. These figures...

MacroGenics to Participate in Upcoming Investor Conference

Written by Customer Service on June 11, 2024. Posted in Public Companies.

ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in the following investor conference this month:Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Thursday, June 13, 2024, at 10:00am ET. MacroGenics’ management will also participate in one-on-one meetings.A webcast of the above presentation may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at...

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Written by Customer Service on June 11, 2024. Posted in Public Companies.

Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company previously announced the initiation of the last pre-clinical study required for a novel-food application submission, in accordance with novel foods and food additives legislation and regulations accepted in many jurisdictions worldwide. Clearmind’s alcohol substitute was granted patents in the U.S., India and Europe. This project is being led by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, serving as...

Lithium Ionic Completes Acquisition of Remaining 15% of Salinas Properties, Minas Gerais, Brazil

Written by Customer Service on June 11, 2024. Posted in Public Companies.

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) reports that, further to its May 30, 2024 press release, its wholly owned subsidiary, Neolit Minerals Participações Ltda (“Neolit”), has completed the acquisition of the remaining 15% of select Salinas properties (“Salinas” or the “Project”), located within the Curralinho Pegmatite Field of the lithium-rich Araçuaí Pegmatite District, in Minas Gerais, Brazil (the “Transaction”). Lithium Ionic now owns 100% of the Salinas group of properties (See Figure 1). As consideration pursuant to the Transaction, the Company has paid the vendor:A cash payment of the Brazilian Real equivalent of US$2 million The issuance of 2.5 million shares of Lithium IonicAdditionally, the Company is required to make a...

Almadex Announces Plans to Drill at Paradise, Acquires Royalty at Willow, and Provides Corporate Update on Mexico

Written by Customer Service on June 11, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce its plan to commence a drill program of approximately 2,000 metres to test lithocap targets recently defined at the Paradise project in Nevada, USA. As described in its news release of February 27th, 2024, Almadex defined a porphyry copper-gold target at Paradise through mapping and soil geochemistry. Further detailed mapping was recently completed on the porphyry target area at the project. This work defined two separate zones of porphyry lithocap alteration:A diaspore-pyrophyllite-dickite-alunite alteration zone interpreted as a potential feeder to underlying porphyry mineralization at Arena Central backed up by elevated Na-content of alunite, Au, Ag,...

Day: June 11, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals